Therapy News and Research

RSS

Cochrane Review rejects safety concerns regarding cheap alternative drug for treating eye disease

Health policies which favour using ranibizumab for treating eye disease in older people over safety concerns for a cheaper alternative should take account of a new Cochrane Review published today.

16 Sep 2014

GHIT Fund announces new grants to tackle malaria, chagas disease and dengue

The Global Health Innovative Technology Fund, a new public health partnership that is bringing Japanese know-how and investment to the global fight against infectious diseases, today announced seven grant investments totaling US$15.3 million to speed the development of promising drugs and vaccines to battle three insect-borne diseases-malaria, dengue and Chagas disease.

16 Sep 2014

WellStar establishes new health park in East Cobb

WellStar East Cobb Health Park opened its doors September 15, serving as a comprehensive, one-stop shop for outpatient medical needs.

15 Sep 2014

Amgen announces phase 3 ivabradine data for treatment of chronic HF

Amgen (NASDAQ: AMGN) today announced data from the Phase 3 SHIFT (Systolic Heart failure treatment with the If inhibitor ivabradine Trial) study evaluating ivabradine in patients with chronic heart failure (HF) were presented at the 18th Annual Scientific Meeting of the Heart Failure Society of America (HFSA) in Las Vegas.

15 Sep 2014

Instrumentation Laboratory announces launch of HemosIL Direct Thrombin Inhibitor Assay in Europe

Instrumentation Laboratory today announced the commercialization in Europe of their HemosIL Direct Thrombin Inhibitor (DTI) Assay. When used in conjunction with HemosIL Dabigatran Calibrators and Controls, this test offers an automated solution for the measurement of dabigatran, a direct oral anticoagulant (DOAC).

15 Sep 2014

Ramucirumab Phase III study meets primary endpoint in patients with metastatic colorectal cancer

Eli Lilly and Company today announced that the RAISE trial, a Phase III study of ramucirumab (CYRAMZA) in combination with chemotherapy in patients with metastatic colorectal cancer (mCRC), met its primary endpoint of overall survival.

15 Sep 2014

Six research institutions awarded NIH grants to create database of human cellular responses

Building on a successful three-year pilot project, the National Institutes of Health has awarded more than $64 million to six research institutions to create a database of human cellular responses, the Library of Integrated Network-based Cellular Signatures.

15 Sep 2014

Three-year safety data from INTREPID study of Oraya Therapy™ for wet age-related macular degeneration results announced

Oraya Therapeutics Inc. announced that full results of three-year safety follow-up data from the INTREPID study of Oraya Therapy™ for wet age-related macular degeneration (AMD) further demonstrated a favorable safety profile and also showed that there was no significant difference in vision outcomes in patients treated with Oraya Therapy compared with those receiving anti-vascular endothelial growth factor (anti-VEGF) injections alone.

15 Sep 2014

Gut hormone-drug combination therapy more effective at improving type 2 diabetes

Combined treatment with a drug that mimics the action of a gut hormone and basal insulin is more effective at improving blood sugar control than other anti-diabetic treatments, with similar rates of hypoglycaemia (dangerously low blood sugar levels) and greater weight loss, a systematic review and meta-analysis published in The Lancet shows.

15 Sep 2014

Researchers find learning and memory components of neurofibromatosis using zebrafish model

Using a zebrafish model of a human genetic disease called neurofibromatosis (NF1), a team from the Perelman School of Medicine at the University of Pennsylvania has found that the learning and memory components of the disorder are distinct features that will likely need different treatment approaches.

15 Sep 2014

Breathing-based meditation practice can be effective treatment for PTSD

One of the greatest casualties of war is its lasting effect on the minds of soldiers. This presents a daunting public health problem: More than 20 percent of veterans returning from the wars in Iraq and Afghanistan have post-traumatic stress disorder, according to a 2012 report by RAND Corp.

12 Sep 2014

AstraZeneca is developing new PARP inhibitor for treatment of ovarian cancer

The ovarian cancer market is highly active with several promising candidates having reached the late stages of development. Three PARP inhibitors, Lynparza (AstraZeneca), niraparib (Tesaro) and rucaparib (Clovis Oncology), which induce cell death in mutated [BRCA-deficient] cancer cells, have been identified by Datamonitor Healthcare as front runners.

11 Sep 2014

Gastroenterologist hopes to achieve healthy growth and development in children around the world

Why is it harder for kids in low- and middle-income countries to grow as well as kids in wealthy countries? Food security, or access to good nutrition, remains a major challenge. The issue is not just food supply but poor sanitation - a problem exacerbated by local infrastructure and cultural mores.

11 Sep 2014

Widespread use of unnecessary antibiotics drives up avoidable healthcare costs

The Centers for Disease Control and Prevention (CDC) and Premier, Inc. have released new research on the widespread use of unnecessary and duplicative antibiotics in U.S. hospitals, which could have led to an estimated $163 million in excess costs.

11 Sep 2014

New book brings awareness to debate surrounding stem cell research

Mary Ann Liebert, Inc., leading publisher of over 80 science, technology, and medical publications, announced today the launch of first time hard cover title Inevitable Collision: The Inspiring Story that Brought Stem Cell Research to Conservative America, in an effort to bring awareness to the growing conversation and debate surrounding stem cell research and regenerative medicine.

11 Sep 2014

Professor receives award for development of anti-angiogenic therapy for retinal disease

Napoleone Ferrara, MD, distinguished professor of pathology and distinguished adjunct professor of ophthalmology at the University of California, San Diego School of Medicine and senior deputy director for basic sciences at UC San Diego Moores Cancer Center, was named today as one of seven recipients of the Ant-nio Champalimaud Vision Award in Lisbon, Portugal.

11 Sep 2014

Clinical trial of stem cell-derived therapy for patients with Type 1 diabetes

Researchers at the University of California, San Diego School of Medicine, in partnership with ViaCyte, Inc., a San Diego-based biotechnology firm specializing in regenerative medicine, have launched the first-ever human Phase I/II clinical trial of a stem cell-derived therapy for patients with Type 1 diabetes.

11 Sep 2014

Researchers create new vestibular test to add to comprehensive concussion evaluation

Researchers at UPMC and the University of Pittsburgh have created a new, 5- to 10-minute test that could be added to a clinician's concussion evaluation toolkit for a more comprehensive assessment of the injury.

11 Sep 2014

Get SET Early: New program to reduce mean age of ASD diagnosis in multiple cities

Autism spectrum disorder (ASD) is now estimated to impact one in every 68 children born in the United States. Yet despite its rising prevalence and the known benefits of early detection and treatment, toddlers in much of the United States are routinely not identified as possibly having ASD until well after their third birthday.

11 Sep 2014

Merck's Keytruda gets FDA approval for treatment of malignant melanoma

The recent approval of Merck & Co.'s Keytruda by the U.S. Food and Drug Administration for the treatment of malignant melanoma is a significant milestone for Merck & Co. and for the oncology immunotherapy drug market. Decision Resources Group anticipates the launch of Keytruda as the first anti-PD-1 immunotherapy in the United States for treatment of advanced and unresectable malignant melanoma.

10 Sep 2014

Therapy News and Research

Cochrane Review rejects safety concerns regarding cheap alternative drug for treating eye disease

GHIT Fund announces new grants to tackle malaria, chagas disease and dengue

WellStar establishes new health park in East Cobb

Amgen announces phase 3 ivabradine data for treatment of chronic HF

Instrumentation Laboratory announces launch of HemosIL Direct Thrombin Inhibitor Assay in Europe

Ramucirumab Phase III study meets primary endpoint in patients with metastatic colorectal cancer

Six research institutions awarded NIH grants to create database of human cellular responses

Three-year safety data from INTREPID study of Oraya Therapy™ for wet age-related macular degeneration results announced

Gut hormone-drug combination therapy more effective at improving type 2 diabetes

Researchers find learning and memory components of neurofibromatosis using zebrafish model

Breathing-based meditation practice can be effective treatment for PTSD

AstraZeneca is developing new PARP inhibitor for treatment of ovarian cancer

Gastroenterologist hopes to achieve healthy growth and development in children around the world

Widespread use of unnecessary antibiotics drives up avoidable healthcare costs

New book brings awareness to debate surrounding stem cell research

Professor receives award for development of anti-angiogenic therapy for retinal disease

Clinical trial of stem cell-derived therapy for patients with Type 1 diabetes

Researchers create new vestibular test to add to comprehensive concussion evaluation

Get SET Early: New program to reduce mean age of ASD diagnosis in multiple cities

Merck's Keytruda gets FDA approval for treatment of malignant melanoma

Industry Focus eBook - Analytical Chemistry (2nd Edition) eBook

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News